

Protalix BioTherapeutics, Inc.  
Form 8-K  
February 09, 2012

---

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

---

**FORM 8-K**

---

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of  
the Securities Exchange Act of 1934**

**Date of Report (Date of Earliest Event Reported): February 9, 2012**

---

**Protalix BioTherapeutics, Inc.**

**(Exact name of registrant as specified in its charter)**

---

Florida                                      001-33357                                      65-0643773  
**(State or other jurisdiction)**   **(Commission File Number)**   **(IRS Employer)**

**of incorporation)**

**Identification No.)**

2 Snunit Street  
Science Park, POB 455  
Carmiel, Israel 20100  
(Address of principal executive offices) (Zip Code)

**Registrant's telephone number, including area code +972-4-988-9488**

**(Former name or former address, if changed since last report.)**

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 8.01. Other Events**

On February 9, 2012, Protalix BioTherapeutics, Inc. (the “Company”) issued a press release announcing that new clinical data on taliglucerase alfa will be presented at the 8th Annual Meeting of the Lysosomal Disease Network: WORLD Symposium 2012 being held February 8-10 in San Diego, California.

A copy of the press release is filed as Exhibit 99.1.

**Item 9.01. Financial Statements and Exhibits**

**(d) Exhibits**

99.1 Press release dated February 9, 2012

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

PROTALIX BIOTHERAPEUTICS, INC.

Date: February 9, 2012 By: /s/ David Aviezer, Ph.D.

Name: David Aviezer, Ph.D.

Title: President and Chief Executive Officer